Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas

Open access
Moreno‐Bueno, Gema, Salvador, Fernando, Martín, Alberto, Floristán, Alfredo, Cuevas, Eva P., Santos, Vanesa, Montes, Amalia, Morales, Saleta, Castilla, Maria Angeles, Rojo‐Sebastián, Alejandro, Martínez, Alejandra, Hardisson, David, Csiszar, Katalin, Portillo, Francisco, Peinado, Héctor, Palacios, José, Cano, Amparo·2011·EMBO Molecular Medicine

Abstract

Basal-like breast carcinoma is characterized by the expression of basal/myoepithelial markers, undifferentiated phenotype, highly aggressive behaviour and frequent triple negative status (ESR-, PR-, Her2neu-). We have previously shown that epithelial-mesenchymal transition (EMT) occurs in basal-like breast tumours and identified Lysyl-oxidase-like 2 (LOXL2) as an EMT player and poor prognosis marker in squamous cell carcinomas. We now show that LOXL2 mRNA is overexpressed in basal-like human breast carcinomas. Breast carcinoma cell lines with basal-like phenotype show a specific cytoplasmic/perinuclear LOXL2 expression, and this subcellular distribution is significantly associated with distant metastatic incidence in basal-like breast carcinomas. LOXL2 silencing in basal-like carcinoma cells induces a mesenchymal-epithelial transition (MET) associated with a decrease of tumourigenicity and suppression of metastatic potential. Mechanistic studies indicate that LOXL2 maintains the mesenchymal phenotype of basal-like carcinoma cells by a novel mechanism involving transcriptional downregulation of Lgl2 and claudin1 and disorganization of cell polarity and tight junction complexes. Therefore, intracellular LOXL2 is a new candidate marker of basal-like carcinomas and a target to block metastatic dissemination of this aggressive breast tumour subtype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/emmm.201100156

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 11 references

Cited by

See all 158

Metadata

Authors
Moreno‐Bueno, G., Salvador, F., Martín, A., Floristán, A., Cuevas, E. P., Santos, V., Montes, A., Morales, S., Castilla, M. A., Rojo‐Sebastián, A., Martínez, A., Hardisson, D., Csiszar, K., Portillo, F., Peinado, H., Palacios, J., & Cano, A.
Venue
EMBO Molecular Medicine
Published
2011-07-06
Volume
3
Issue
9
Pages
528-544
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W1894499695
Cited by
158
References
11
FWCI
6.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas. https://app.cochat.ai/papers/10.1002/emmm.201100156
The paper
Moreno‐Bueno, G., Salvador, F., Martín, A., Floristán, A., Cuevas, E. P., Santos, V., Montes, A., Morales, S., Castilla, M. A., Rojo‐Sebastián, A., Martínez, A., Hardisson, D., Csiszar, K., Portillo, F., Peinado, H., Palacios, J., & Cano, A. (2011). Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.201100156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.